Stockscreener 앱 받기
0.00
100.00%
-1.71
전일 마감가:
$1.71
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$10.59M
수익:
-
순이익/손실:
$-35.80M
주가수익비율:
0.00
EPS:
-2.97
순현금흐름:
$-37.18M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$27.78
Aptose Biosciences Inc Stock (APTO) Company Profile
명칭
Aptose Biosciences Inc
전화
310-849-8060
주소
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
APTO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
0.00 | 10.59M | 0 | -35.80M | -37.18M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.43 | 114.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
535.97 | 55.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
305.72 | 39.64B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
570.15 | 35.64B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.23 | 28.55B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-10-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-02-20 | 개시 | Maxim Group | Buy |
| 2020-02-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-09 | 개시 | Piper Sandler | Overweight |
| 2019-03-01 | 개시 | RBC Capital Mkts | Outperform |
| 2018-11-16 | 개시 | B. Riley FBR | Buy |
| 2017-12-13 | 재확인 | H.C. Wainwright | Buy |
| 2017-10-23 | 재개 | ROTH Capital | Buy |
| 2017-09-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2017-06-08 | 개시 | Rodman & Renshaw | Neutral |
모두보기
Aptose Biosciences Inc 주식(APTO)의 최신 뉴스
(APS) Investment Analysis and Advice (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Reports Promising Results from TUSCANY Trial in AML - MSN
Aptose Presents Safety, Response, and MRD Clinical Data from TUS - GuruFocus
Aptose reports promising data from TUS+VEN+AZA therapy for AML By Investing.com - Investing.com South Africa
Aptose reports promising data from TUS+VEN+AZA therapy for AML - Investing.com Canada
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - The Manila Times
APTOAptose Announces Reverse Share Split - Revista ADVFN
Where are the Opportunities in (APS) (APS:CA) - news.stocktradersdaily.com
(APS) Financial Trading Report (APS:CA) - news.stocktradersdaily.com
(APS) Technical Pivots with Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose's Closing of US$3M Investment by Hanmi Pharmaceutical - McCarthy Tétrault
Aptose Biosciences completes Public Offering of Common Shares for US$74.2M - McCarthy Tétrault
Aptose Biosciences Inc. enters into exclusive license agreement with Hanmi Pharmaceutical - McCarthy Tétrault
Aptose Biosciences Inc. Completes US$4.43M Registered Direct Offering and Concurrent Private Placement - McCarthy Tétrault
Aptose Biosciences Inc. announces it entered into a $25M Committed Equity Facility - McCarthy Tétrault
Aptose enters equity distribution agreement with Piper Sandler and Canaccord Genuity - McCarthy Tétrault
Aptose Announces Results from Annual and Special Meeting of Shar - GuruFocus
Aptose Announces Results from Annual and Special Meeting of Shareholders - The Globe and Mail
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and Aptose Biosciences (NASDAQ:APTO) - Defense World
Trading (APS) With Integrated Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com - Defense World
(APS) Investment Performance Report (APS:CA) - news.stocktradersdaily.com
Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada
Stocks In Play: Aptose Biosciences Inc. - Barchart.com
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee | APTOF Stock N - GuruFocus
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee - The Manila Times
(APS) Advanced Equity Analysis (APS:CA) - news.stocktradersdaily.com
Aptose Selected for Prestigious Oral Presentation of Data from T - GuruFocus
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - St. Catharines Standard
StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences Reports Q1 2025 Financial Results - TipRanks
(APS) On The My Stocks Page (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences: Q1 Earnings Snapshot - CT Insider
Aptose Biosciences Reports Promising AML Trial Results and Expands Market Presence - TipRanks
Aptose Biosciences Inc. SEC 10-Q Report - TradingView
Aptose Reports First Quarter 2025 Results - The Manila Times
(APS) Market Performance Analysis (APS:CA) - news.stocktradersdaily.com
In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML - insights.citeline.com
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com - Defense World
(APS) Technical Patterns and Signals (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Inc. - Baystreet.ca
Aptose Biosciences Reports Promising Results from TUSCANY Trial for AML Treatment - TipRanks
Aptose Provides Clinical Update for Tuspetinib-based Triple Drug Therapy in Tuscany Trial - marketscreener.com
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial - The Manila Times
Breakthrough AML Treatment: Triple Drug Therapy Shows Complete Remission in Patients with Resistant Mutations - Stock Titan
Aptose Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Comparing Sana Biotechnology (NASDAQ:SANA) & Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences Inc (APTO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.97%
0.52%
자본화:
|
볼륨(24시간):